What is Cagrilintide?
Cagrilintide is a lipidated, long-acting analogue of human amylin that acts across amylin and calcitonin receptors. It is supplied here as a lyophilised powder for in-vitro laboratory research only.
Key concepts
- Analogue of amylin (IAPP), not of an incretin hormone
- Acts at calcitonin receptor / RAMP complexes
- Engineered for both long action and reduced aggregation
- Most often studied in combination with GLP-1 receptor agonists
- Aggregation state should be checked by an orthogonal method for stored solutions
- Functional receptor complex depends on the RAMP partner expressed in the model
- Cagrilintide’s receptor pharmacology is distinct from the GLP-1/GIP/glucagon incretin system
- Monomeric state should be confirmed before functional assays are interpreted as pharmacology
Amylin, not an incretin
Amylin (islet amyloid polypeptide) is co-secreted with insulin from pancreatic beta cells and acts on receptor complexes formed by the calcitonin receptor together with receptor activity-modifying proteins. Cagrilintide is a synthetic analogue of that hormone, not of GLP-1 or GIP.
This matters when designing experiments: the receptor system involved is distinct from the incretin receptors, so a cagrilintide experiment probes a different signalling pathway even when the endpoint being measured looks similar.
Why native amylin needed re-engineering
Human amylin is strongly amyloidogenic and aggregates readily, which makes the native sequence unsuitable as a long-acting research peptide. Analogue design therefore has two objectives at once: extending duration of action and suppressing the tendency to aggregate.
Cagrilintide addresses both through sequence substitution and lipidation, the same albumin-binding strategy used in long-acting incretin analogues. In practical terms, aggregation behaviour is the property that most affects handling of amylin analogues in the laboratory.
Combination research
Because amylin and incretin receptor signalling are separate pathways, the literature frequently examines cagrilintide alongside a GLP-1 receptor agonist rather than as a standalone comparator. Combination designs of that kind are the main reason laboratories order it with semaglutide or tirzepatide.
Interpretation of combination work requires the single-agent arms to be characterised in the same system, otherwise additive and non-additive effects cannot be distinguished.
How it is supplied for research
Biovanta Research supplies cagrilintide as lyophilised powder in 5mg and 10mg vials, each batch independently assayed with the certificate published before sale.
Material is supplied strictly for in-vitro laboratory research by qualified persons. It is not a medicine and is not for human or veterinary use.
Analytical verification
Because amylin analogues are prone to aggregation, HPLC-based purity testing for cagrilintide is particularly important for detecting soluble aggregate species alongside simple chemical degradation products, and mass spectrometry confirms the intact monomer mass. As with other peptides in this library, the certificate of analysis issued for the specific batch is the correct reference for identity and purity, not a general literature value.
Laboratories working with amylin analogues over extended periods may also wish to periodically re-check aggregation state by an orthogonal method such as size-exclusion chromatography or dynamic light scattering, particularly if a solution has been stored for longer than the short-term window recommended for reconstituted material.
Model systems for amylin research
Recombinant cell lines co-expressing the calcitonin receptor with a receptor activity-modifying protein are the standard system for isolating amylin receptor pharmacology from other signalling pathways. Central nervous system tissue and rodent feeding models are used in the literature to study satiety-related endpoints, and co-culture or co-administration designs are used for combination work with incretin peptides.
Because functional amylin receptors depend on the specific RAMP partner expressed, the receptor complex present in a given cell line should be confirmed rather than assumed, since expression of the calcitonin receptor alone does not guarantee a native amylin-receptor pharmacology profile.
Development and regulatory status
Cagrilintide remains investigational. Clinical interest is concentrated on combination regimens with GLP-1 receptor agonists, reported in early- and mid-stage trials, but it does not hold a marketing authorisation from the MHRA or equivalent regulators, and no human dosing or efficacy conclusions can be drawn from the current published record.
Where cagrilintide sits relative to the incretin peptides
Cagrilintide is grouped in this library alongside the incretin peptides because it is studied for related metabolic endpoints, but its receptor pharmacology is entirely separate: it acts through amylin/calcitonin receptor complexes rather than through GLP-1, GIP or glucagon receptors. This distinction is the reason cagrilintide is rarely used as a standalone comparator for semaglutide, tirzepatide or retatrutide, and is instead studied either on its own terms or in combination designs.
Readers moving between the incretin and amylin sections of this library should treat the two as separate pharmacological systems that happen to converge on related physiological endpoints, rather than as variations on a single receptor theme.
Study design considerations for amylin analogue research
Because functional amylin receptor pharmacology depends on the specific receptor activity-modifying protein co-expressed with the calcitonin receptor, a well-designed cagrilintide study confirms and reports which RAMP is present in the chosen cell line rather than assuming a native-like receptor complex is formed by default. Concentration-response curves should also be run against a native amylin or an established reference analogue calibrator in every assay run.
Because the peptide is prone to aggregation, experiments intended to measure genuine receptor pharmacology should include a check that the material used is predominantly monomeric at the start of the assay, since aggregated material can behave differently in a functional assay independent of any true pharmacological effect.
Tracking the literature and registry entries
The cagrilintide literature is smaller and more recent than for the established incretin peptides, so a standing PubMed search combined with regular review of ClinicalTrials.gov entries for cagrilintide and for its combination regimens is a practical way to keep track of new findings as they are published. Because much of the current clinical interest is in combination with GLP-1 receptor agonists, registry searches should include those combination trial names as well as cagrilintide alone.
As with all compounds in this library, any statement about cagrilintide’s mechanism or research findings should be checked against the primary paper before being generalised, and material supplied for laboratory use carries no dosing or human-use guidance.
Strength of the current evidence
Amylin receptor pharmacology is well described. The clinical literature on cagrilintide is smaller and earlier-stage than for the incretin peptides, and combination findings remain investigational.
References
- Indexed cagrilintide publications (PubMed search listing)
- Amylin receptor pharmacology literature (PubMed search listing)
- Registered cagrilintide studies (ClinicalTrials.gov search listing)
Back to the Cagrilintide research hub · Cagrilintide research material · Certificates of analysis
Research use only. Everything on this page describes published laboratory and preclinical research into a compound supplied strictly for in-vitro research by qualified persons. It is not medical advice, it does not describe human or veterinary use, and no dosing guidance is given.